DALI—the first human whole-blood low-density lipoprotein and lipoprotein (a) apheresis system in clinical use: procedure and clinical results

摘要: Background The DALI low-density lipoprotein (LDL) apheresis system is the first whole-blood in regular clinical use. stands for direct adsorption of lipoproteins, which describes basic principle operation this newly developed LDL procedure. Methods selective removal LDLs and (a) [Lp(a)] performed human whole blood by onto polyacrylate-coated polyacrylamide beads an adsorber. This article results open multicentre trial 14 patients whom safety efficacy were tested. All treated on average 17 times a weekly basis. In total, 238 sessions carried out during study without severe side-effects. On average, 767 5 mL patients' was processed about 2 h. Anticoagulation extracorporeal giving heparin bolus followed continuous addition acid citrate dextrose (ACD-A) infusion treatment. Results processing ofnearly 1.6 patient volumes resulted reduction median LDL-cholesterol level 66-77% (dependent configuration). Lp(a) concentrations reduced 59-73% HDL-cholesterol, cell count other parameters not significantly affected. Conclusion Based short-term evaluation, well-tolerated, effective simple way reducing blood. has been introduced to practice. However, use routine, further evaluation long-term effects required.